Schramek et al. reported that in vivo administration of MPA triggered massive induction of the key osteoclast differentiation factor RANKL in mammary-gland epithelial cells, markedly increasing the risk of developing breast cancer [21]. The gene discussed is TNFSF11; the disease is breast carcinoma.